Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -77,14 +77,8 @@
77	77
78	78	In 1858, Dr. Edward Robinson Squibb, a naval surgeon, established his own pharmaceutical laboratory in Brooklyn, New York, after being dissatisfied with the quality and purity of the drugs available at the time. In 1887, William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical Company in Clinton, New York, and renamed it Bristol, Myers & Company. In 1898, Squibb Corporation introduced the first commercially available ether inhaler for anesthesia. In 1900, Bristol-Myers Company launched Sal Hepatica, a laxative mineral salt, and Ipana, the first toothpaste to contain a disinfectant. In 1924, Squibb Corporation became the first company to produce insulin in the United States, in collaboration with the University of Toronto. In 1941, Squibb Corporation developed penicillin, the first antibiotic, in partnership with the US government and other companies. In 1957, Bristol-Myers Company acquired Cheplin Biological Laboratories, a producer of antibiotics, vitamins, and vaccines. In 1960, Bristol-Myers Company introduced Bufferin, the first buffered aspirin, and Excedrin, the first extra-strength pain reliever. In 1972, Squibb Corporation launched Capoten, the first angiotensin-converting enzyme (ACE) inhibitor, for the treatment of hypertension and heart failure. In 1984, Bristol-Myers Company merges with Squibb Corporation, creating Bristol-Myers Squibb, one of the world’s largest pharmaceutical companies. In 1989, Bristol-Myers Squibb acquired Mead Johnson & Company, a leader in infant and child nutrition. In 1991, Bristol-Myers Squibb introduced Taxol, a breakthrough drug for the treatment of ovarian and breast cancer. In 1996, Bristol-Myers Squibb launched Zerit, the first once-daily antiretroviral drug for HIV/AIDS. In 2001, Bristol-Myers Squibb acquired DuPont Pharmaceuticals, expanding its portfolio of cardiovascular and oncology drugs. In 2007, Bristol-Myers Squibb introduced Orencia, the first biologic therapy for rheumatoid arthritis. In 2009, Bristol-Myers Squibb acquired Medarex, a biotechnology company specializing in monoclonal antibodies. In 2012, Bristol-Myers Squibb launched Eliquis, a novel oral anticoagulant for the prevention of stroke and blood clots. In 2015, Bristol-Myers Squibb acquired Flexus Biosciences, a developer of immuno-oncology drugs. In 2019, Bristol-Myers Squibb acquired Celgene, a biopharmaceutical company focused on hematology and oncology.
79	79
80		-In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines. In August, the business announced it would acquire Forbius and its TGF-beta 1 & TGF-beta 3 inhibitors. In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224. In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically repotrectinib.{{footnote}}https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/{{/footnote}} In August 2023, Bristol Myers Squibb partnered with Cellares for the robotic production of CAR-T treatments of which it has two approved. In September 2023, BMS announced it would pay Zenas BioPharma $50m upfront for a strategic license and collaboration to develop and commercialise obexelimab, a novel, bi-functional antibody for autoimmune diseases. In October 2023, BMS agreed to acquire Mirati Therapeutics, an American biotechnology company that develops targeted therapies for the treatment of cancer, in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment. Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The company entered into an agreement to purchase RayzeBio, for approximately $4.1 billion, in December 2023.{{footnote __cke_selected_macro="true"}}https://www.bloomberg.com/news/articles/2023-12-26/bristol-myers-adds-to-buying-spree-with-radiological-drugmaker?{{/footnote}}
	80	+In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines. In August, the business announced it would acquire Forbius and its TGF-beta 1 & TGF-beta 3 inhibitors. In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224. In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically repotrectinib.{{footnote}}https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/{{/footnote}} In August 2023, Bristol Myers Squibb partnered with Cellares for the robotic production of CAR-T treatments of which it has two approved. In September 2023, BMS announced it would pay Zenas BioPharma $50m upfront for a strategic license and collaboration to develop and commercialise obexelimab, a novel, bi-functional antibody for autoimmune diseases. In October 2023, BMS agreed to acquire Mirati Therapeutics, an American biotechnology company that develops targeted therapies for the treatment of cancer, in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment. Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The company entered into an agreement to purchase RayzeBio, for approximately $4.1 billion, in December 2023.{{footnote}}https://www.bloomberg.com/news/articles/2023-12-26/bristol-myers-adds-to-buying-spree-with-radiological-drugmaker?{{/footnote}}
81	81
	82	+= References =
82	82
83		-
84		-
85		-
86		-
87		-
88		-
89		-
90	90	{{putFootnotes/}}